Testing the Substrate-Envelope Hypothesis with Designed Pairs of Compounds by Shen, Yang et al.
Testing the Substrate-Envelope Hypothesis with Designed Pairs of
Compounds
Yang Shen,†,○,¶,# Michael D. Altman,‡,⊥,# Akbar Ali,§,∥,# Madhavi N. L. Nalam,§ Hong Cao,§,∥
Tariq M. Rana,*,∥,∇ Celia A. Schiﬀer,*,§ and Bruce Tidor*,†,○
†Department of Biological Engineering, ‡Department of Chemistry, and ○Department of Electrical Engineering and Computer
Science, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, United States
§Department of Biochemistry and Molecular Pharmacology and ∥Chemical Biology Program, University of Massachusetts Medical
School, Worcester, Massachusetts 01605, United States
∇Sanford-Burnham Medical Research Institute, La Jolla, California 92037, United States
*S Supporting Information
ABSTRACT: Acquired resistance to therapeutic agents is a
signiﬁcant barrier to the development of clinically eﬀective
treatments for diseases in which evolution occurs on clinical
time scales, frequently arising from target mutations. We
previously reported a general strategy to design eﬀective
inhibitors for rapidly mutating enzyme targets, which we
demonstrated for HIV-1 protease inhibition [Altman et al. J.
Am. Chem. Soc. 2008, 130, 6099−6113]. Speciﬁcally, we
developed a computational inverse design procedure with the
added constraint that designed inhibitors bind entirely inside
the substrate envelope, a consensus volume occupied by natural substrates. The rationale for the substrate-envelope constraint is
that it prevents designed inhibitors from making interactions beyond those required by substrates and thus limits the availability
of mutations tolerated by substrates but not by designed inhibitors. The strategy resulted in subnanomolar inhibitors that bind
robustly across a clinically derived panel of drug-resistant variants. To further test the substrate-envelope hypothesis, here we
have designed, synthesized, and assayed derivatives of our original compounds that are larger and extend outside the substrate
envelope. Our designs resulted in pairs of compounds that are very similar to one another, but one respects and one violates the
substrate envelope. The envelope-respecting inhibitor demonstrates robust binding across a panel of drug-resistant protease
variants, whereas the envelope-violating one binds tightly to wild type but loses aﬃnity to at least one variant. This study provides
strong support for the substrate-envelope hypothesis as a design strategy for inhibitors that reduce susceptibility to resistance
mutations.
Many chemical and biological agents have been developedto deliver quality-of-life improvements, especially in
health care and agriculture. Advances include herbicides and
pesticides, as well as medical tests, treatments, and
interventions. However, therapeutic and environmental agents
impose selective pressure that can lead to acquired resistance.
Although resistance can be attained through many mecha-
nisms,1−6 for infectious diseases and cancer, in particular,
mutation of the direct target is often the source of resistance
and is associated with accelerated mutation rates. Such
resistance limits the eﬀectiveness of therapies that are time-
consuming and expensive to develop and approve through
regulatory processes. Thus, it is crucial to devise general
strategies to incorporate into standard drug discovery
paradigms that lead to elimination of resistance or at least to
a large reduction in its incidence. Often the targets are enzymes
essential to disease maintenance or progression. For such cases,
the development of inhibitors that are as similar as possible to
the disease-related substrates has been hypothesized as an
eﬀective strategy for reducing resistance.7 The notion behind
such substrate mimicry is that enzyme mutations that reduce
inhibitor binding would then, by similarity arguments, be very
likely to also reduce substrate binding and possibly also
turnover, and thus not be well tolerated. Inhibitors that are
similar to substrates thus restrict resistance by introducing
signiﬁcantly higher genetic barriers that must be surmounted in
their presence.
HIV-1 protease has proven an extremely useful case for
studying the development and avoidance of resistance. HIV-1
protease was the ﬁrst therapeutic target for which structure-
based drug design was broadly applied.8 Ten HIV-1 protease
inhibitors have been approved by the U.S. FDA since the
1990s. All but tipranavir9 are peptidomimetics that are similar
to transition-state analogues of substrates, including saquina-
vir,10 ritonavir,11 indinavir,12 nelﬁnavir,13 amprenavir14/fosam-
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prenavir,15 lopinavir,16 atazanavir,17 and darunavir.18 These
drugs allow longer life expectancy for AIDS patients but still fall
short of a cure. Therapeutic failure is due to rapid evolution of
viral strains and accumulation of resistance-endowing mutations
under selective drug pressure. In an eﬀort to understand how
drug-resistant HIV-1 protease maintains the ability to recognize
and cleave its substrates, the Schiﬀer group compared the
crystal structures of an inactive variant of HIV-1 protease with
six peptides that correspond to the natural substrate cleavage
sites.19 It was discovered that the protease recognizes the
substrates of diverse sequences through an asymmetric shape
commonly adopted by the substrates, whose surface has been
referred to as “the substrate envelope”. The same group further
showed that many inhibitors protrude beyond the substrate
envelope and make contacts with enzyme residues not
contacted by substrates and that are the sites of primary
resistance mutations.7 It was thus hypothesized that “an
inhibitor contained within the substrate envelope, interacting
only with the same residues that are necessary to recognize
substrate, may be less susceptible to drug resistance.”7 This so-
called “substrate-envelope hypothesis” was assessed in a
computational framework for inhibitors of HIV-1 protease20,21
as well as Abl kinase, chitinase, thymidylate synthase, DHFR,
and neuraminidase.22 It was shown that the volume of an
inhibitor molecule that protrudes outside the substrate
envelope correlates with average mutation sensitivity. Recent
crystallography data and analyses suggested that the substrate-
envelope hypothesis also applies to the inhibitors of the NS3/
4A protease, a target for hepatitis C virus (HCV) infection.23,24
Implementing a general strategy to design robustly eﬀective
inhibitors for mutatable enzyme targets, we previously
performed computational inverse design of HIV-1 protease
inhibitors that reside inside the substrate envelope.25 Promising
candidates were synthesized, assayed, and characterized, which
led to the identiﬁcation of subnanomolar inhibitors to drug-
resistant variants. Thirty-six compounds (comprising the
MIT-2 library) were potent inhibitors of wild-type HIV-1
protease, with Ki values ranging from 14 pM to 4 nM. Ten of
the most potent inhibitors were further assayed in antiviral
activity against a panel of four drug-resistant HIV-1 protease
Table 1. Parent Compounds (AD-93 and KB-83) and Designed New Compounds
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variants derived from clinically isolated, drug-resistant strains.
Two compounds remained potent against the panel with less
than 15-fold aﬃnity loss, and four had moderate shifts of less
than 80-fold loss.25
In this study, we further investigate the implications of the
substrate-envelope hypothesis in designing robust inhibitors
that are of low susceptibility to drug-resistance mutations. The
scaﬀold forming the basis of the MIT-2 library was adopted
from amprenavir and darunavir, the latter of which has an
especially ﬂat resistance proﬁle. Thus, we sought to investigate
whether the relatively high incidence of these compounds with
ﬂat binding proﬁles in the MIT-2 library was due to their being
designed to bind within the substrate envelope or was instead a
result of their being based on an advantageous scaﬀold. Here,
we computationally designed two series of compounds that
progressively protrude outward toward and through the
substrate envelope but are otherwise identical, in order to
isolate the eﬀect of the substrate-envelope constraint and study
its impact on binding speciﬁcity proﬁles; all compounds in the
current study share the amprenavir/darunavir scaﬀold. Eight
compounds were designed based on two MIT-2 parent
compounds, with protrusions beyond various subpockets of
the binding site (including two levels of protrusions at the P1′
site). Two compounds that were predicted and shown
experimentally to violate signiﬁcantly the substrate envelope
were shown to bind tightly to wild type but poorly to members
of the mutant panel; in contrast, the parent compounds respect
the substrate envelope and are ﬂat binders against the panel,
with less than 50-fold aﬃnity loss. Four newly designed
compounds that essentially respect the substrate envelope were
also ﬂat binders. Taken together these results indicate that the
six broadly binding compounds along with earlier designs25
beneﬁt from residing fully within the substrate envelope and
thus decreasing the chance of losing interactions with a drug-
resistant variant, rather than beneﬁtting from an advantaged
scaﬀold. Moreover, the substrate-envelope violators lost the
most binding aﬃnity to protease variants with mutations nearby
the site of the violation. Thus, these results greatly strengthen
the notion that the substrate-envelope hypothesis provides a
valuable framework for developing enzyme inhibitors that are
robust against both wild type and resistant variants.
■ RESULTS AND DISCUSSION
Drug-resistant mutations in HIV-1 protease occur in various
positions and combinations. Principles for the design of
therapeutics that avoid resistance mutations for HIV-1 protease
and other targets would be valuable. The substrate-envelope
hypothesis is a general principle for avoiding resistant variants
for enzyme targets. Here we further tested the substrate-
envelope hypothesis by designing paired inhibitors of HIV-1
protease that diﬀer only in whether they respect the substrate
envelope, chemically synthesizing them, and performing
inhibitory and antiviral activity assessments.
Computational Design of Inhibitors. Computational
molecular design was applied to target the HIV-1 protease
active site using a design library consisting of a scaﬀold with
three variable positions. The goal was to probe changes in
binding speciﬁcity as increasing functional group size
approached and eventually pierced the substrate envelope.
Two parent compounds reported previously were selected for
this study, MIT-2-AD-93 and MIT-2-KB-83, chosen for their
high aﬃnities and relatively ﬂat binding proﬁles.25 Designs were
carried out in the wild-type active site, using larger substituents
that are allowed to pierce the substrate envelope. From the sets
of predicted high-aﬃnity designs, we selected eight molecules
for synthesis and testing that had functional groups larger than
those in the corresponding parent compound and thus probed
the substrate envelope with the potential to extend beyond it
(Table 1).
The selected compounds involve the same single sub-
stitutions to both parent compounds, with an N-acetyl-
isoleucine substitution at R1, a smaller cyclohexylmethyl and
a larger 3-phenylpropyl hydrophobic substitution at R2, and 5-
(isoxazol-5-yl)-2-thiophene at R3. The numbers of non-
hydrogen atoms in the substitutions (original function group)
were 9 (7), 7 (4 or 5), 9 (4 or 5), and 10 (8 or 9), respectively,
which corresponds to a net increase of 1−5 non-hydrogen
atoms in each substitution.
Inhibitor Synthesis and Activity. The compounds were
synthesized (see Methods for synthetic methods and
compound characterization). They were assayed for inhibitory
activity against wild type and a panel of drug-resistant protease
variants using modiﬁed high-throughput enzyme inhibition
assays compared to the original characterization of the parent
compounds.25,26 The mutant panel included two multi-drug-
resistant variants M1 (L10I, G48V, I54V, V82A) and M3
Table 2. Measured Binding Aﬃnity Values against Wild-Type and Mutant Panel
wild typea
M1 (L10I, G48V, I54V,
V82A)a
M2 (D30N,
N88D)a
M3 (L10I, A71V, G73S, I84V,
L90M)a
M4 (I50V,
A71V)a
worst-fold aﬃnity
lossb
AD-93 0.046 ± 0.023 0.724 ± 0.377 0.905 ± 0.124 1.713 ± 1.042 1.920 ± 0.834 41
AG-23 0.021 ± 0.009 0.376 ± 0.168 0.028 ± 0.025 0.048 ± 0.022 0.092 ± 0.025 18
AF-72 0.129 ± 0.028 1.328 ± 0.851 0.383 ± 0.097 2.753 ± 0.609 4.823 ± 3.116 37
AF-69 0.070 ± 0.005 19.18 ± 3.84 2.004 ± 0.298 9.965 ± 0.530 2.265 ± 0.643 274
AF-71 3.329 ± 0.663 18.20 ± 8.12 2.951 ± 0.128 44.82 ± 22.42 30.04 ± 3.79 13
KB-83 0.194 ± 0.007 1.560 ± 0.124 0.283 ± 0.097 2.021 ± 0.033 1.101 ± 0.241 10
AF-68 0.146 ± 0.071 0.819 ± 0.255 0.049 ± 0.034 1.029 ± 0.134 0.144 ± 0.115 7
AF-77 0.546 ± 0.028 2.045 ± 0.502 0.490 ± 0.100 2.469 ± 0.860 3.404 ± 0.593 6
AF-78 0.437 ± 0.132 42.93 ± 0.559 2.543 ± 0.462 23.80 ± 4.17 5.887 ± 2.755 98
AF-80 2.493 ± 0.251 28.13 ± 1.37 1.261 ± 0.176 10.53 ± 0.16 13.53 ± 4.10 11
aThe measured Ki of each inhibitor to each enzyme is given as the mean ± standard deviation, in units of nM. Measurements are reported for wild-
type HIV-1 protease as well as for four drug-resistant variants (M1, M2, M3, and M4) for which the speciﬁc mutations are given in parentheses, with
the key resistance mutations in bold face (relative to the PDB ID 1T3R wild type). bThe worst-fold loss is given as the weakest Ki to one of the drug-
resistant variants (bold face) divided by the Ki to wild type for each inhibitor.
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(L10I, A71V, G73S, I84V, L90M), a signature variant of
nelﬁnavir resistance M2 (D30N, N88D), and a signature
variant of amprenavir and darunavir resistance M4 (I50V,
A71V). (In each case the boldface mutations are the primary
drug-resistant ones.) The inhibition data for the parent and
variant compounds against the panel are given in Table 2.
Because all inhibitors appear to act competitively, we interpret
the measured inhibition constants (Ki) as inhibitor aﬃnities
(disassociation constants Kd).
The parent compounds are potent, subnanomolar binders to
wild-type protease and show ﬂat resistance proﬁles across the
panel of resistant variants. The binding proﬁle is characterized
using two metrics, the worst-fold aﬃnity loss and the weakest
binding aﬃnity. The worst-fold aﬃnity loss is the ratio between
the weakest binding aﬃnity (Ki) of a compound for a protease
variant and its aﬃnity for wild-type protease. Speciﬁcally, AD-
93 (KB-83) had a wild-type aﬃnity of 0.046 nM (0.19 nM) and
41-fold (10-fold) loss against the mutant panel, where the
weakest binding aﬃnity was 1.92 nM (2.02 nM) measured with
the M4 (M3) variant. Several observations were made for the
new compounds. (1) Relative to the parent compounds, six of
the eight new compounds had comparable or improved binding
aﬃnity with wild-type protease. The two exceptions, AF-71 and
AF-80, both involved the same substitution at R3, remained
nanomolar binders to wild-type protease, but suﬀered 72-fold
and 13-fold loss, respectively, in aﬃnity compared to their
respective parent compounds. (2) The binding speciﬁcity
proﬁles of the new compounds fall into two classes: six that
remained potent or had a moderate shift against the mutant
panel (<50-fold aﬃnity loss) and two that were more
susceptible to resistance mutations (>80-fold aﬃnity loss).
The latter two, AF-69 and AF-78, both involve the large 3-
phenylpropyl hydrophobic substitution at R2 and in the crystal
structures showed a large expected violation of the substrate
envelope (see Table 3). Both suﬀered their largest aﬃnity loss
when binding variant M1. Interestingly, AF-71 and AF-80, the
two relatively weak binders to wild-type protease, had rather ﬂat
binding speciﬁcity proﬁles with worst-fold aﬃnity losses of 13
and 11, respectively. This is consistent with a common
perception that it is less diﬃcult to identify broadly binding
compounds with low aﬃnity than it is to ﬁnd broadly binding
ones with high aﬃnity.27 (3) Of the 10 compounds, six
maintained subnanomolar to nanomolar aﬃnity in their
weakest complexes. They include parent compounds and new
compounds involving the N-acetyl-isoleucine substitution at R1
or the smaller cyclohexylmethyl substitution at R2. In both the
AD-93 and the KB-83 series, the larger 3-phenylpropyl
hydrophobic substitutions at R2 and the 5-(isoxazol-5-yl)-2-
thiophene substitutions at R3 resulted in weakest binding
aﬃnities, with Ki’s greater than 20 nM.
In designing potent inhibitors that are of low susceptibility to
resistance mutations, it is not clear which metric, weakest
binding aﬃnity or worst-fold aﬃnity loss, is more important.
Therefore, we show in Figure 1 a two-dimensional plot of both
metrics for all 10 compounds against the wild-type and mutant
panel. The lower-left corner of the plot indicates where ideal
low-susceptibility inhibitors would lie. Inhibitors located here
have both tight and ﬂat binding speciﬁcity proﬁles. AG-23, AF-
68, and AF-77 are the best compounds judged by this type of
Pareto optimality; that is, no other compound achieves lower
values in both weakest binding aﬃnity and worst-fold aﬃnity
loss. One would shift priority from AG-23 to AF-68 and then to
AF-77 as increasing priority was put on worst-fold aﬃnity loss
relative to worst binding aﬃnity.
Crystal Structures of Bound Complexes. To understand
further the resistance patterns described above, crystal
structures were solved for the complexes of wild-type HIV-1
protease and all eight new compounds. The AD-93 and KB-83
complexes were reported previously25 (PDB accession codes
2QI4 and 3SA8, respectively). These crystal structures are
shown in Figure 2 (AD-93 series) and Figure 3 (KB-83 series).
Violations of the substrate envelope were computed from the
crystal structures (total and decomposition by functional
groups are given in Table 3; crystallographic details are in
Methods and Supplementary Table 1). For the 10 compounds,
observed envelope violation volumes correlated well with
corresponding substituent sizes in the designed structures.
Parent compounds AD-93 and KB-83, both ﬂat binders, had
negligible violation of the substrate envelope. New compounds
with small violations all displayed ﬂat speciﬁcity proﬁles. In
particular, AG-23, AF-72, AF-68, and AF-77 did not violate the
substrate envelope by more than 15.2 Å3, which is smaller than
the volume of a carbon atom (20.6 Å3 in the model used here),
Table 3. Measured Substrate Envelope Violations (in Å3)
and Their Decompositions
compound total R1 (near P2) R2 (near P1′) R3 (near P2′)
AD-93 7.8 0.5 0.0 5.1
AG-23 11.0 2.1 0.8 4.8
AF-72 13.6 0.3 6.2 5.5
AF-69-A/Ba 14.5/20.0 1.1/0.1 6.0/13.4 5.8/5.7
AF-71 19.9 0.3 0.0 17.4
KB-83-A/Ba 7.4/10.1 0.4/3.0 0.0 5.2
AF-68 10.9 2.3 0.0 6.3
AF-77 15.2 0.2 6.7 5.9
AF-78-A/Ba 29.0/29.5 0.1/0.6 21.5 5.7
AF-80 20.3 0.5 0.0 18.2
a“A/B” indicates that there exist two conformations (A and B) that
often have equal occupancies. The atomic volumes of substrate-
envelope violations for these compounds were provided as in the two
conformations separated by “/”(where applicable).
Figure 1. Pareto plot of aﬃnity and speciﬁcity. Plot shows two metrics
for each of 10 inhibitors studied, weakest binding aﬃnity and worst
fold loss, against the wild-type and mutant panel.
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and the maximum worst-fold aﬃnity loss across the set is 37.
These substrate-envelope violation volumes are calculated to be
a little higher than those for amprenavir (3.73 Å3) or darunavir
(4.10 Å3) that have low susceptibility to drug-resistant
variations but are much lower than those for drugs with high
susceptibility, such as saquinavir (80.40 or 64.73 Å3; PDB
accession code 3OXC28 [A or B]). In contrast, compounds
with substantial substrate-envelope violations had poor
speciﬁcity proﬁles. In particular, AF-69 (in conformation B
with 50% occupancy) and AF-78 (in both conformations A and
B with equal occupancies) had violations of about 20 and 29 Å3,
respectively, which are comparable to 1−1.5 carbon atoms, and
their worst-fold aﬃnity loss was 274 and 98, respectively. There
seems to be a relationship between the location at which an
inhibitor protrudes outside the substate envelope and the
mutant sustaining the greatest loss in aﬃnity. Namely, binding
is most sensitive to mutations near that envelope violation,
which might be most likely to disrupt interactions with the
protruding group. For example, the greatest structural
violations of both AF-69 and AF-78 were due to the R2
group, where the same bulky hydrophobic substitution
(3-phenylpropyl) was introduced, and their weakest binding
aﬃnities were measured with M1, which includes the P1′ site
mutations (G48V and V82A) near where R2 packs in the
bound complex. Taken together, the data presented here show
that zero or small violations of the substrate envelope can lead
to compounds with relatively ﬂat binding proﬁles and that
larger violations can produce inhibitors that are susceptible to
resistant variants. This is by no means a highly quantitative
relationship; for example, compounds with larger envelope
violations can have smaller worst-fold aﬃnity losses (AF-78 vs
AF-69), particularly against a relatively small panel of mutants.
Note that two compounds violate the envelope but bind
robustly across the mutant panel. AF-71 and AF-80, involving
the same R3 substitution with a double-ring aromatic system,
had violation amounts of about 20 Å3 but worst-fold aﬃnity
losses of only about 10. In the P2′ site surrounding the R3
group, only one residue (Asp 30) is involved in the mutations
included in the mutant panel (D30N in M2). However, AF-71
and AF-80 have improved aﬃnity with M2 compared to that of
Figure 2. Crystal structures of AD-93 series. Proteases are shown in gray cartoon with sticks representing side chains that are mutated in the mutant
panel. One-letter amino acid code and residue index are used to label these residues, color-coded by various drug-resistant variants (blue for M1,
green for M2, orange for M3, and purple for M4). These structures are aligned and viewed from the top (ﬂap region), and this view was applied to all
panels in Figures 2 and 3. All compounds are represented as van der Waals spheres. Carbon atoms are gray for proteases and cyan for inhibitors. The
remaining atoms follow the same color-coding rule: red for oxygen, blue for nitrogen, and yellow for sulfur (hydrogen atoms are not shown). A gray,
half-transparent surface around each compound represents the substrate envelope. Thus parts of spheres that are not veiled by the gray surface
correspond to atomic volumes that pierce the substrate envelope. (A) AD-93, (B) AG-23, (C) AF-72, (D) AF-69, conformation A, (E) AF-69,
conformation B, (F) AF-71.
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wild type. This is consistent with the notion that the panel does
not have mutations nearby that can challenge these violations,
but that these inhibitors could bind poorly to other functional
HIV-1 protease variants with more disruptive mutations in the
vicinity. Interestingly, the solved X-ray crystal structure had a
second conformation for AF-69 (conformation A), which had a
smaller R2 violation. If these are both equally accessible, one
might imagine that binding to mutants could occur in at least
conformation A, and so the loss in aﬃnity would be minor
(kbTln2). That this is not the case could be due to unequal
occupancy of these two conformations.
Antiviral Activity Proﬁles of Inhibitors. Cell-based
antiviral assays were carried out by Monogram Biosciences
(South San Francisco, CA) using a panel of various strains of
wild-type and variant proteases (Table 4). Four designed
compounds that all respected the substrate envelope were
tested (the Pareto optimal AG-23 and AF-68 and the somewhat
bulkier AF-72 and AF-77) together with two FDA-approved
Figure 3. Crystal structures of KB-83 series. See the caption of Figure 2 for details. (A) KB-83, conformation A (conformation B of compound KB-
83 only diﬀers slightly in R1 compared to conformation A and is thus not shown here), (B) AF-68, (C) AF-77, (D) AF-78, conformation A, (E) AF-
78, conformation B, (F) AF-80.
Table 4. Antiviral Activity (EC50 Values in nM) against Selected Wild-Type and Drug-Resistant HIV Clones
wild-type
(CNDO
control
strain)a
wild-type clade A
(I13V, E35D, M36I,
R41K, H69K,
L89M)a
wild-type clade
B (N37H,
R41K, V77I,
I93L)a
wild-type clade C
(I15V, M36I, R41K,
H69K, L89M,
I93L)a
MDRC4 (L10I, G16E,
R41K, M46I, I54V,
L63T, T74S, V82A,
I93L)b
MDR1 (L10I, T12K, N37T,
R41K, M46I, I54V, D60E, I62V,
L63P, I64V, V77I, V82A,
L90M)
worst-
fold
activity
lossc
amprenavir 3.0 2.6 1.8 3.7 17.5 15.6 5.5
darunavir 0.25 0.3 0.15 0.18 0.6 0.23 2.4
AG-23 2.7 2.3 1.9 3.5 8.7 7.2 3.2
AF-72 63.7 48.6 37.9 94.6 165.2 99.1 2.6
AF-68 3.5 2.4 1.6 3.0 15.4 15.1 4.4
AF-77 47.3 38.4 22.4 65.7 105.5 86.9 2.2
aWild-type control strain CNDO and patient-derived strains of wild-type HIV-1 from clades A, B, and C . bMDRC4, multi-drug-resistant control
strain R268. (Genbank accession numbers for all strains are given in the Supporting Information; mutant residues listed here are relative to the
CNDO wild-type control strain.). cThe worst-fold loss is given as the weakest EC50 value to one of the variants (bold face) divided by that to wild-
type for each inhibitor.
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drugs (amprenavir and darunavir, whose inhibition and antiviral
activities were previously characterized25,26). All four designed
compounds had ﬂat antiviral activity proﬁles across the viral
panel with worst-fold activity losses of between 2.2 and 4.4,
which were comparable to those of amprenavir (5.5) and
darunavir (2.4). In terms of absolute antiviral activity against
wild-type virus, the EC50’s of AG-23 (2.7 nM) and AF-72 (3.5
nM) were similar to that of amprenavir (5.5 nM) but an order
of magnitude weaker than that of darunavir (0.25 nM). The
EC50’s of AF-68 (63.7 nM) and AF-77 (47.4 nM) were another
order of magnitude higher. Taken together, these results further
strengthen the substrate-envelope hypothesis, by showing that
the ﬂat binding proﬁles of envelope-respecting compounds
extends to ﬂat activity proﬁles.
Conclusion. In this study, we provide a detailed test of the
substrate-envelope hypothesis as a means of designing robust
inhibitors against drug-resistant variants. While the use of
substrate and transition-state analogues as a starting point for
inhibitor design is common, the rationale there is one of
achieving aﬃnity: because substrates and transition-states bind
to the target, their analogues could bind as well. The substrate-
envelope hypothesis relies on more detailed substrate mimicry
so the inhibitor does not inadvertently rely on binding
interactions nonessential to substrates and thus susceptible to
resistance mutations. In other words, the goal of substrate-
envelope mimicry is to borrow speciﬁcity rather than just
aﬃnity from substrates.
To this end, two series of related HIV-1 protease inhibitors
were computationally designed. Compounds within each series
probed single functional group changes that expanded toward
and eventually breached the substrate envelope. Aﬃnity,
speciﬁcity, and antiviral activity assays were performed on the
synthesized compounds using drug-resistant panels of protease
and virus, and complexes with the wild-type protease were
structurally characterized with X-ray crystallography.
Although all compounds share the amprenavir/darunavir
scaﬀold, which is associated with relatively ﬂat binding proﬁles,
we found pairs of compounds that diﬀered by only a single
functional group that bound to the wild-type enzyme in a
similar manner with similar aﬃnity but diﬀered greatly in their
ability to inhibit drug-resistant proteases variants (AD-93 vs
AF-69 and KB-83 vs AF-78). The single distinguishing feature
separating ﬂat from nonﬂat binders in these pairs was that ﬂat
binders respected (AD-93 and KB-83) and nonﬂat binders
violated (AF-69 and AF-78) the substrate envelope. This
suggests that the envelope is more important than the shared
scaﬀold in the development of inhibitors of low susceptibility to
drug-resistant mutations.
Interestingly, mutations in the protease occur near diﬀerent
locations on the envelope. There is excellent correspondence
between losses in aﬃnity and the location of envelope-violating
inhibitor excursions. AF-69 and AF-78 both have R2 extensions
that violate the envelope at P1/P1′, and both inhibitors lose
their greatest aﬃnity to the M1 variant with characteristic
mutations G48V and V82A, which are close to the envelope at
P1/P1′, consistent with the notion that the inhibitors violate
the envelope to make non-substrate-like P1/P1′ interactions
that are disturbed in the M1 variant. In contrast, two of the
designed compounds, AF-71 and AF-80, violate the envelope
substantially but exhibit ﬂat binding proﬁles against the mutant
panel. As they involve the same R3 substitution and the panel
lacks mutations in the P2/P2′ site nearby, we predict that they
would become susceptible to other drug-resistant variants that
are not present in the panel studied. In other words, these two
cases should not be regarded as counterexamples of the
substrate-envelope hypothesis but rather examples showcasing
potential predictive powers of the hypothesis.
Although the substrate-envelope hypothesis, in a narrow
sense, applies only to enzyme targets, one can generalize the
envelope hypothesis for non-enzyme targets through extending
the deﬁnition of the envelope to include other necessary
functions of a target besides binding substrates. Consequen-
tially, designed compounds that hide inside some “envelope of
function” could be immune to target mutations that maintain
native function.
■ METHODS
Computational Design. In our previous study,25 36 MIT-2
compounds were computationally designed, and the binding speciﬁcity
proﬁles for 10 of them against the wild-type and mutant panel were
experimentally measured. Two compounds that exhibited ﬂat binding
proﬁles, namely, MIT-2-AD-93 and MIT-2-KB-83, were chosen as
parent compounds. A 1.2-Å crystal structure of darunavir-bound wild-
type HIV-1 protease (PDB accession code 1T3R) was used as the
ﬁxed target into which inhibitor compounds were computationally
designed. All inhibitors share the (R)-(hydroxyethylamino)-
sulfonamide scaﬀold derived from the clinically approved inhibitors
amprenavir14 and darunavir18 but possess various functional groups
(that attach to the scaﬀold at diﬀerent positions) derived from the
ZINC database29 and commercial catalogs. The same design
framework and parallel synthetic components were used for the
previously reported MIT-2 library.25 The special design strategy here
was to compare the lists of top candidates designed with the substrate-
envelope constraint and the maximal-envelope constraint, identify
functional group choices at each position that violate the substrate-
envelope constraint and are otherwise energetically favored against the
background of other positions, and generate the list of derivative
compounds that are one functional group away from each parent
compound covering various positions and molecular properties.
Synthesis. The designed protease inhibitors were synthesized
using a stepwise synthetic approach. The Boc-protected intermediates
(R)-(hydroxyethylamino)sulfonamides 5−12 (Scheme 1) were
prepared from the commercially available chiral epoxide 1, (1S,2S)-
(1-oxiranyl-2-phenylethyl)carbamic acid tert-butyl ester, using methods
described previously.25,30 Brieﬂy, regioselective ring-opening of
epoxide 1 with selected primary amines 2a−d provided the β-amino
alcohols 3a−d, respectively. Selective reactions of secondary amino
group in 3a−d with 4-methoxybenzene sulfonyl chloride using
aqueous sodium carbonate (Na2CO3) and with bezothiazole-6-sulfonyl
chloride and 5-(isoxazol-5-yl)thiophene-2-sulfonyl chloride using
diisopropylethylamine in anhydrous CH2Cl2 provided the (R)-
(hydroxyethylamino)sulfonamide intermediates 5−12. Removal of
the Boc protection using triﬂuoroacetic acid in CH2Cl2 followed by the
reactions of the resulting free amines with carboxylic acids 13a,b using
either EDCI/HOBt/DIEA in a DMF−CH2Cl2 (1:1) mixture (Method
A) or EDCI/HOBt in a H2O−CH2Cl2 (1:1) mixture (Method B)25
provided the designed inhibitors 14−21.
Assays for Inhibition and Antiviral Activities. HIV protease
inhibitor activities were determined by the ﬂuorescence resonance
energy transfer (FRET) method.31,32 Protease substrate, Arg-Glu-
(EDANS)-Ser-Gln-Asn-Tyr-Pro-Ile-Val-Gln-Lys(DABCYL)-Arg, was
labeled with the energy transfer donor (EDANS) and acceptor
(DABCYL) dyes at its two ends to perform FRET. Fluorescence
measurements were carried out on an EnVision plate reader
(PerkinElmer). Drug susceptibility assays were carried out by
Monogram Biosciences against wild-type HIV-1 control, three
patient-derived strains of wild-type HIV-1 from clades A, B, and C,
and two multi-drug-resistant HIV-1 variants including MDRC4 as
control strain and MDR1 strain with protease mutations M46I, I54V,
V82A, and L90M.
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Crystallography. The expression, isolation, and puriﬁcation of
wild-type and drug-resistant HIV-1 protease variants used for
crystallization and binding experiments were carried out as previously
described.33 More details are provided in Supporting Information. The
data collection and reﬁnement statistics are shown in Supplementary
Table 1.
Structural Analysis. The wild-type protease-inhibitor crystallo-
graphic complexes were evaluated in terms of substrate-envelope
hypothesis. The extent to which an inhibitor violates the substrate
envelope was measured by the volume of its non-hydrogen atoms that
protrude outside (calculated in total or decomposed at various sites).
The protrusion volume was calculated based on a grid with 0.2-Å
spacing.
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